Premium
Post‐transplant malignant neoplasia associated with cyclosporine‐based immunotherapy: prevalence, risk factors and survival in feline renal transplant recipients
Author(s) -
Wormser C.,
Mariano A.,
Holmes E. S.,
Aronson L. R.,
Volk S. W.
Publication year - 2016
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12120
Subject(s) - medicine , cats , lymphoma , transplantation , gastroenterology , population , odds ratio , kidney transplantation , urology , environmental health
The study objective was to compare the prevalence of malignant neoplasia in feline renal transplant recipients ( n = 111) with a control population of cats that did not receive transplantation ( n = 142); and to determine whether the development of post‐transplant malignant neoplasia ( PTMN ) affects long‐term survival. Twenty‐five (22.5%) renal transplant recipients were diagnosed with PTMN , and of those 14 (56%) were diagnosed with lymphoma. The overall survival time in cats that developed PTMN following renal transplantation (median 646 days, IQR 433–1620 days) was not significantly different from the survival time in cats that did not develop PTMN (median 728 days, IQR 201–1942 days), although median survival after diagnosis of PTMN was only 13 days. Six control cats (4.2%) were diagnosed with malignant neoplasia. Compared to the control population, transplant cats had a 6.6 times higher odds of developing malignant neoplasia and a 6.7 times higher odds of developing lymphoma.